Hasnain Ahmed Malik

This inventor holds 8 USPTO granted patents and 5 published patent applications and 4 EPO patents. Top assignee: Novartis Ag. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hasnain Ahmed Malik. Retrieved from https://idiyas.com/inventor/hasnain-ahmed-malik

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 5)

% Patents Active = 87.5

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 10.8

ph-index = 1

Forward Citations = 5(Granted Patents)

Company Filing History:

8 out of 3,977

Novartis Ag

patents

Years Active: 2019-2026

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12570625 - 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF (2026-03-10),

2. 12252482 - Pyrazolopyridine derivatives and uses thereof (2025-03-18),

3. 12172984 - Pyrazolopyridine derivatives and uses thereof (2024-12-24),

4. 11787785 - Pyrazolopyridine derivatives and uses thereof (2023-10-17),

5. 11566022 - 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof (2023-01-31),

6. 11192877 - 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof (2021-12-07),

7. 11066369 - N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease (2021-07-20),

8. 10450273 - N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease (2019-10-22),

Title: Innovations of Hasnain Ahmed Malik

Introduction

Hasnain Ahmed Malik is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for inherited blood disorders. With a total of 7 patents to his name, Malik's work is recognized for its potential impact on medical science.

Latest Patents

Among his latest patents are the Pyrazolopyridine derivatives and their uses. These compounds are designed to reduce the expression levels of Widely Interspaced Zinc Finger Motifs (WIZ) and induce fetal hemoglobin (HbF) expression. This innovation holds promise for the treatment of inherited blood disorders, including sickle cell disease and beta-thalassemia.

Career Highlights

Hasnain Ahmed Malik is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on groundbreaking research and development in the pharmaceutical sector. His contributions have been instrumental in advancing therapeutic options for patients suffering from serious blood disorders.

Collaborations

Malik collaborates with talented professionals in his field, including Simone Bonazzi and Artiom Cernijenko. These collaborations enhance the innovative potential of his research and contribute to the overall success of their projects.

Conclusion

Hasnain Ahmed Malik's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and research efforts are paving the way for new treatments that could significantly improve the lives of individuals with inherited blood disorders.

Profile summary based on public USPTO records.